NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
79.22 +0.96 (+1.23%) GOLD FUTURES
2,343.40 -31.60 (-1.33%) DOW
39,431.64 -81.20 (-0.21%) Bitcoin GBP
50,260.84 +1,366.40 (+2.79%)
NVO Jan 2026 195.000 call
| Previous close | 6.85 |
| Open | 6.85 |
| Bid | 7.35 |
| Ask | 7.95 |
| Strike | 195.00 |
| Expiry date | 2026-01-16 |
| Day's range | 6.75 - 6.85 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
Globe NewswireNovo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors. The trial achieved its co-primary endp
- Reuters
UPDATE 2-Denmark faces Wegovy shortage due to rising demand
Denmark faces a supply shortage for two doses of Novo Nordisk's Wegovy weight-loss drug in the coming months due to rising demand, the Danish Medicines Agency said on Monday. The hugely popular Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes. There will be a shortage of Novo Nordisk's Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.
